XL-protein: the PASylation company
  • About
    • Corporate overview
    • Corporate strategy
    • Leadership team
  • Technology
    • Technology
    • PAS-Advantages
    • Intellectual property
  • Partnering
    • Partnering
  • News and Publications
    • Key publications
    • Various publications
    • Press archive
    • Receive our Press Releases
  • Careers
  • Contact
    • Contact
    • Imprint
    • Disclaimer
    • Privacy Policy
  • Search

Link

Hoffmann K., Milech N., Juraja S.M., Cunningham P.T., Stone S.R., Francis R.W., Anastasas M., Hall C.M., Heinrich T., Bogdawa H.M., Winslow S., Scobie M.N., Dewhurst R.E., Florez L., Ong F., Kerfoot M., Champain D., Adams A.M., Fletcher S., Viola H.M., Hool L.C., Connor T., Longville B.A.C., Tan Y.F., Kroeger K., Morath V., Weiss G.A., Skerra A., Hopkins R.M., Watt P.M. (2018) A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery. Sci. Rep. 8, 12538.

⇒ Abstract

Link

Friedrich L., Kornberger P., Mendler C.T., Multhoff G., Schwaiger M., Skerra A. (2018) Selection of an Anticalin® against the membrane form of Hsp70 via bacterial surface display and its theranostic application in tumour models. Biol. Chem. 14, 235-252.

⇒ Abstract

Link

Ahmadpour S., Hosseinimehr S. J. (2018) PASylation as a powerful technology for improving the pharmacokinetic properties of biopharmaceuticals. Curr. Drug Deliv. 15, 331-341.

⇒ Abstract

Link

Khodabakhsh F., Norouzian D., Vaziri B., Ahangari Cohan R., Sardari S., Mahboudi F., Behdani M., Mansouri K., Mehdizadeh A. (2017) Molecular design, expression and evaluation of Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties. Artif. Cells Nanomed. Biotechnol. 22, 39.

⇒ Abstract

Link

Zvonova E. A., Ershov A. V., Ershova O.A., Sudomoina M. A., Degterev M. B., Poroshin G. N., Eremeev A. V., Karpov A. P., Vishnevsky A. Y., Goldenkova-Pavlova I. V., Petrov A. V., Ruchko S. V., Shuster A. M. (2017) PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity. Appl. Microbiol. Biotechnol. 101, 1975-1987.

⇒ Abstract

Link

Hedayati M. H., Norouzian D., Aminian M., Teimourian S., Ahangari Cohan R., Sardari S., Khorramizadeh M. R. (2017) Molecular design, expression and evaluation of PASylated human recombinant erythropoietin with enhanced functional properties. Protein J. 36, 36-48.

⇒ Abstract

Link

Harder M. J., Kuhn N., Schrezenmeier H., Höchsmann B., von Zabern I., Weinstock C., Simmet T., Ricklin D., Lambris J. D., Skerra A., Anliker M., Schmidt C. Q. (2016) Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood 129, 970-980.

⇒ Abstract

Link

Zelikin A.N., Ehrhardt C. and Healy A.M. (2016) Materials and methods for delivery of biological drugs. Nat. Chem. 8, 997-1007.

⇒ Abstract

Link

Lerchner A., Daake M., Jarasch A., Skerra A. (2016) Fusion of an alcohol dehydrogenase with an aminotransferase using a PAS linker to improve coupled enzymatic alcohol-to-amine conversion. Protein Eng. Des. Sel. 29, 557-562.

⇒ Abstract

Link

Mendler C. T., Feuchtinger A., Heid I., Aichler M., D’Alessandria C., Pirsig S., Blechert B., Wester H. J., Braren R., Walch A., Skerra A., Schwaiger M. (2016) Tumor uptake of anti-CD20 Fabs depends on tumor perfusion. J. Nucl. Med. 57, 1971-1977.

⇒ Abstract

Link

Chhabra K. H., Adams J. M., Jones G. L. , Yamashita M., Schlapschy M., Skerra A., Rubinstein M. and Low M. J. (2016) Reprogramming the body weight set point by a reciprocal interaction of hypothalamic leptin sensitivity and Pomc gene expression reverts extreme obesity.
Mol. Metab. 5, 869–881.

⇒ Abstract

Link

Bolze F., Bast A., Mocek S., Morath V., Yuan D., Rink N., Schlapschy M., Zimmermann A., Heikenwalder M., Skerra A., Klingenspor M. (2016) Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation. Diabetologia 59, 2005-2012.

⇒ Abstract

Link

Fracasso G., Falvo E., Colotti G., Fazi F., Ingegnere T., Amalfitano A., Doglietto G.B., Alfieri S., Boffi A., Morea V., Conti G., Tremante E., Giacomini P., Arcovito A., Ceci P. (2016) Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness. J. Control. Release 239, 10-18.

⇒ Abstract

Link

Falvo E., Tremante E., Arcovito A., Papi M., Elad N., Boffi A., Morea V., Conti G., Toffoli G., Fracasso G., Giacomini P., Ceci P. (2016) Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements. Biomacromolecules 17, 514-522.

⇒ Abstract

Link

Mendler C. T., Gehring T., Schwaiger M., Wester H.J., Skerra A. (2015) 89Zr-labeled versus 124I-labeled αHER2 Fab with optimized plasma half-life for high-contrast tumor imaging in vivo. J. Nucl. Med. 56, 1112-1118.

⇒ Abstract

Breibeck J., Serafin A., Reichert A., Maier S., Küster B., Skerra A. (2014) PAS-cal: a generic recombinant peptide calibration standard for mass spectrometry. J. Am. Soc. Mass Spectrom. 25, 1489-1497.

⇒ Abstract

Press releases

  • Ajinomoto and XL-protein forge Strategic Alliance to develop PASylated therapeutics applying the Corynex® platform 18. December 2018
  • Horizon Pharma plc and XL-protein GmbH have entered into a collaboration agreement on a potential next-generation biologic for uncontrolled gout using PASylation® technology 7. January 2018
  • AdAlta and XL-protein execute commercial license agreement 13. November 2017
© 2018 - All Rights Reserved for XL-protein GmbH | Imprint | Disclaimer | Data Privacy Policy
  • Mail
Scroll to top